I31901PCT

Figure 1:





Figure 1 (cont.)

C



D




Figure 2:

a)



relative expression
adipose tissue 7.5 P
adrenal gland 1.6 A
artery 2.6 A
bone marrow 21.1 P
brain, whole 1.1 A
breast 5.3 A
colon 7.0 P
esophagus 11.3 P
gallbladder 7.5 P
heart 1.4 A
kidney 1.0 A
leukocytes 6.1 A
leukocytes, dendritic cells 4.9 P
liver 1.2 A
lung 6.1 P
lymph node 17.1 P
lymphocytes, CD19+ 1.9 A
lymphocytes, CD3+ 4.3 A
pancreas 3.2 A
placenta 4.9 P
prostate 1.1 A
salivary gland 3.7 A
skeletal muscle 10.9 A
skin 9.2 P
small intestine 9.8 P
spleen 6.1 P
stomach 4.9 A
testis 32.0 P
thymus 9.2 P
thyroid 4.3 A
trachea 4.0 A
urinary bladder 10.9 A
uterine cervix 5.7 A
uterus 1.3 A
vein 10.6 P
GC22157T 42.2 P
GC2228M 119.4 P
GC22307T 128.0 P
GC22341T 78.8 P
GC24191T 32.0 P
GC24231T 64.0 P
GC24241T 90.5 P
GC24261T 90.5 P
GC24271T 59.7 P
GC24281T 68.6 P
GC24301T 48.5 P
GC24321T 36.8 P
GC24331T 64.0 P
GC24351T 207.9 P
GC24361T 111.4 P
GC24371T 42.2 P
GC24471T 39.4 P
GC24481T 68.6 P
GC24491T 22.6 P
GC24511T 207.9 P
GC24611T 26.0 P
GC24661T 119.4 P
GC27021T 119.4 P
GC27031T 90.5 P
GC27051T 111.4 P

Figure 2 (cont.)

b)




Figure 3:



A*2402/CDC2-001
A*2402/Negative control stimulation
A*2402/Negative control multimer
0.020
0.010
95.681
4.298
0.030
0.000
99.970
0.000
A*2402/CDC2-001 multimer
A*2402/ASPM-002
A*2402/Negative control stimulation
A*2402/ASPM-002 multimer
8.552
0.000
91.438
0.010
0.029
0.010
99.932
0.019
A*2402/Negative control multimer

Figure 4



relative TUMAP presentation
0
20
40
60
80
100
Brain 1022
Colon 723
Colon 743
Colon 747
Colon 749
Colon 720
Kidney 212
Kidney 215
Kidney 2216
Kidney 2224
Kidney 2229
Kidney 270
Kidney 5001
Kidney 614
Liver 702
Liver 707
Lung 4002
Lung 912
Lung 914
Lung 991
Pancreas 704
Stomach 702
Stomach 703
GB1008
GB1011
GB1012
GB1014
GB1020
GB1021
GB1023
GB1026
GB6003
GB6010
GB6011
GB6015
GB6016
GB6019
GB6024
GB6027
ND
ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND

Figure 5



Relative TUMAP presentation
0%
20%
40%
60%
80%
100%
120%
CCA718N
RCC178N
RCC212N
RCC220 5N
RCC221 6N
RCC222 3N
RCC222 4N
RCC222 6N
RCC222 9N
RCC294N
NSCLC803N
NSCLC814N
GC2273N
GC2274N
GC2275N
GC703N
GC716N1
GC716N6
GC719N3
GC719N5
GC719N6
GC725N1
GC730N3
GC2404T
GC2405T
GC2456T
GC2463T
GC2468T
GC703T
GC2402T
GC2411T
GC2433T
GC2436T
GC2451T
GC2453T
GC2455T
GC2466T
GC705T
GC2215T
GC2234T
GC2273T
GC2274T
GC2275T
GC2276T
GC2414T
GC2415T
GC2432T
GC2434T
GC2440T
GC2442T
GC2448T
GC2449T
GC2450T
GC2461T
GC2464T
GC2465T
ND

Figure 6



Normalized area
0.E+00
5.E+06
1.E+07
2.E+07
2.E+07
3.E+07
3.E+07
CCA718N
RCC178N
RCC212N
RCC22005N
RCC22216N
RCC22223N
RCC22224N
RCC22226N
RCC22229N
RCC2294N
NSCLC803N
NSCLC814N
GC2273N
GC2274N
GC22275N
GC703N
GC716N1
GC716N6
GC719N3
GC719N5
GC719N6
GC725N1
GC730N3
GC2404T
GC24057T
GC24056T
GC24637T
GC24687T
GC703T
GC24021T
GC24111T
GC24331T
GC24361T
GC24511T
GC24531T
GC24557T
GC24667T
GC705T
GC22157T
GC22347T
GC22737T
GC22747T
GC22757T
GC22767T
GC24147T
GC24157T
GC24327T
GC24347T
GC24407T
GC24427T
GC24487T
GC24497T
GC24507T
GC246117T
GC24647T
GC24657T
ND
NA

Figure 7







Figure 8





LC-MS runs of sample 969

Figure 9


normal tissues
tumor sample
blood sample
RNA
HLA ligands
PBMCs
microarray gene expression analysis
mass spectrometry
immunoassays
0.00%
0.82%
78.36%
20.81%
m/z
2
1
3
overexpressed genes
over-presented TUMAPs
TUMAP-specific T cells
4
literature research
TUMAP candidates for vaccination
5



Intensity
1.0E+05
7.5E+04
5.0E+04
2.5E+04
122
124
126
128
130
132
134
Retention time (min)
519
520
521
522
m/z

Figure 10